<p style="font-size: 13px;">The GTJA Investment Group has led a $45 million series B round in Akeso Biopharma, a Chinese innovative biotechnology company. Shenzhen Capital Group Co., Ltd., Qianhai Fund of Funds and TriWise Capital also participated in the round, according to a company announcement. Founded in 2012 and headquartered in Guangdong province, Akeso focuses on developing innovative antibody drugs for the Chinese markets.</p>